FDA Accepts Nuvo's Resubmission For Pennsaid(R)
August 5, 2009
MISSISSAUGA, ON
,
Feb. 19
/PRNewswire-FirstCall/ – Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has accepted Nuvo’s resubmission of its application for FDA approval to market Pennsaid in the Read the rest of this entry »